JP2014502974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502974A5 JP2014502974A5 JP2013549683A JP2013549683A JP2014502974A5 JP 2014502974 A5 JP2014502974 A5 JP 2014502974A5 JP 2013549683 A JP2013549683 A JP 2013549683A JP 2013549683 A JP2013549683 A JP 2013549683A JP 2014502974 A5 JP2014502974 A5 JP 2014502974A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- hept
- use according
- cyclopentyl
- enyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 17
- 150000003180 prostaglandins Chemical class 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 13
- 229960001160 latanoprost Drugs 0.000 claims 12
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 12
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 9
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- -1 (Z) -7-[(1R, 2R, 5S) -5-hydroxy-2-[(E, 3S) -3-hydroxyoct-1-enyl] -3-oxocyclopentyl] -hept-5-ene Chemical compound 0.000 claims 7
- 229960002470 bimatoprost Drugs 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 229960002368 travoprost Drugs 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 6
- 208000020925 Bipolar disease Diseases 0.000 claims 5
- 102000001267 GSK3 Human genes 0.000 claims 5
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 5
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 4
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 4
- 102000006378 Catechol O-methyltransferase Human genes 0.000 claims 4
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 4
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims 4
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 4
- 108010062431 Monoamine oxidase Proteins 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 claims 4
- 238000001802 infusion Methods 0.000 claims 4
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims 4
- 229960003987 melatonin Drugs 0.000 claims 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims 4
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims 4
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 4
- CBOMORHDRONZRN-QLOYDKTKSA-N prostaglandin E3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CBOMORHDRONZRN-QLOYDKTKSA-N 0.000 claims 4
- DZUXGQBLFALXCR-CDIPTNKSSA-N prostaglandin F1alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-CDIPTNKSSA-N 0.000 claims 4
- SAKGBZWJAIABSY-SAMSIYEGSA-N prostaglandin F3alpha Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O SAKGBZWJAIABSY-SAMSIYEGSA-N 0.000 claims 4
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 claims 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 4
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 4
- UQZVCDCIMBLVNR-TWYODKAFSA-N sulprostone Chemical compound O[C@@H]1CC(=O)[C@H](C\C=C/CCCC(=O)NS(=O)(=O)C)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 UQZVCDCIMBLVNR-TWYODKAFSA-N 0.000 claims 4
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 claims 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims 2
- OOAHNJDZICJECC-BHWPLRMJSA-N (z)-7-[(1r,2r,3r)-2-[(e,3r)-3-hydroxy-4,4-dimethyloct-1-enyl]-3-methyl-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](C)CC(=O)[C@@H]1C\C=C/CCCC(O)=O OOAHNJDZICJECC-BHWPLRMJSA-N 0.000 claims 2
- OOAHNJDZICJECC-AYLJQANUSA-N (z)-7-[(1r,3r)-2-[(e,3r)-3-hydroxy-4,4-dimethyloct-1-enyl]-3-methyl-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC(C)(C)[C@H](O)\C=C\C1[C@H](C)CC(=O)[C@@H]1C\C=C/CCCC(O)=O OOAHNJDZICJECC-AYLJQANUSA-N 0.000 claims 2
- VJGGHXVGBSZVMZ-YAOROIPCSA-N (z)-7-[(1r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid Chemical compound C([C@H](O)\C=C\C1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-YAOROIPCSA-N 0.000 claims 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 claims 2
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 102000015554 Dopamine receptor Human genes 0.000 claims 2
- 108050004812 Dopamine receptor Proteins 0.000 claims 2
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims 2
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 2
- 229940123934 Reductase inhibitor Drugs 0.000 claims 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 229960000711 alprostadil Drugs 0.000 claims 2
- 230000007131 anti Alzheimer effect Effects 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 229960003965 antiepileptics Drugs 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- 229940005529 antipsychotics Drugs 0.000 claims 2
- 239000003420 antiserotonin agent Substances 0.000 claims 2
- 239000002249 anxiolytic agent Substances 0.000 claims 2
- 230000000949 anxiolytic effect Effects 0.000 claims 2
- 229940005530 anxiolytics Drugs 0.000 claims 2
- 229940125717 barbiturate Drugs 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 150000001557 benzodiazepines Chemical class 0.000 claims 2
- 229960000623 carbamazepine Drugs 0.000 claims 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 2
- 239000000064 cholinergic agonist Substances 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- 229960004409 cloprostenol Drugs 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 229950007806 delprostenate Drugs 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 2
- 229960002986 dinoprostone Drugs 0.000 claims 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960001123 epoprostenol Drugs 0.000 claims 2
- 229950009951 fluprostenol Drugs 0.000 claims 2
- 229960002870 gabapentin Drugs 0.000 claims 2
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 2
- 229960003480 gemeprost Drugs 0.000 claims 2
- KYBOHGVERHWSSV-VNIVIJDLSA-N gemeprost Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC KYBOHGVERHWSSV-VNIVIJDLSA-N 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000007917 intracranial administration Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 229960001848 lamotrigine Drugs 0.000 claims 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- 229960001078 lithium Drugs 0.000 claims 2
- FNAMRDZHKYQEBA-YDQNNXAVSA-N methyl (2e,5z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hepta-2,5-dienoate Chemical compound COC(=O)\C=C\C\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(Cl)=C1 FNAMRDZHKYQEBA-YDQNNXAVSA-N 0.000 claims 2
- KYBOHGVERHWSSV-WUZYGKFZSA-N methyl (e)-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-2-enoate Chemical compound CCCCC(C)(C)[C@@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC KYBOHGVERHWSSV-WUZYGKFZSA-N 0.000 claims 2
- OZDSQCVLNUIYLN-OVFHROADSA-N methyl (z)-7-[(1r,3r,5s)-2-[(3s)-5-cyclohexyl-3-hydroxypent-1-ynyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound COC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)C1C#C[C@@H](O)CCC1CCCCC1 OZDSQCVLNUIYLN-OVFHROADSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229960005249 misoprostol Drugs 0.000 claims 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 2
- 229940126403 monoamine reuptake inhibitor Drugs 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 239000004031 partial agonist Substances 0.000 claims 2
- 230000010412 perfusion Effects 0.000 claims 2
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 2
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 claims 2
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- SPOAFZKFCYREMW-FWYLUGOYSA-N rioprostil Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCCO SPOAFZKFCYREMW-FWYLUGOYSA-N 0.000 claims 2
- 229950004712 rioprostil Drugs 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 229940121356 serotonin receptor antagonist Drugs 0.000 claims 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 2
- 229940084026 sodium valproate Drugs 0.000 claims 2
- 229960003400 sulprostone Drugs 0.000 claims 2
- 229960004394 topiramate Drugs 0.000 claims 2
- 239000003204 tranquilizing agent Substances 0.000 claims 2
- 230000002936 tranquilizing effect Effects 0.000 claims 2
- 229950008298 trimoprostil Drugs 0.000 claims 2
- 229960004317 unoprostone Drugs 0.000 claims 2
- 229950008081 unoprostone isopropyl Drugs 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021030 Hypomania Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000013843 drug-induced mental disease Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- SODMOUXEPOJRRF-UHFFFAOYSA-N hepta-2,5-dienoic acid Chemical compound CC=CCC=CC(O)=O SODMOUXEPOJRRF-UHFFFAOYSA-N 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 210000003516 pericardium Anatomy 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 210000003954 umbilical cord Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161435546P | 2011-01-24 | 2011-01-24 | |
| US61/435,546 | 2011-01-24 | ||
| PCT/CA2012/050037 WO2012100347A1 (en) | 2011-01-24 | 2012-01-24 | Compositions comprising a prostaglandin for treating neuropsychiatric conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502974A JP2014502974A (ja) | 2014-02-06 |
| JP2014502974A5 true JP2014502974A5 (enExample) | 2015-02-05 |
| JP6023082B2 JP6023082B2 (ja) | 2016-11-09 |
Family
ID=46580158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549683A Expired - Fee Related JP6023082B2 (ja) | 2011-01-24 | 2012-01-24 | 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9259409B2 (enExample) |
| EP (1) | EP2667875A4 (enExample) |
| JP (1) | JP6023082B2 (enExample) |
| CA (1) | CA2860453C (enExample) |
| WO (1) | WO2012100347A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012021107A2 (en) | 2010-08-12 | 2012-02-16 | Nanyang Technological University | A liposomal formulation for ocular drug delivery |
| CA2860453C (en) * | 2011-01-24 | 2020-04-28 | Inceptum Research & Therapeutics, Inc. | Compositions comprising a prostaglandin for treating neuropsychiatric conditions |
| AU2012293157A1 (en) * | 2011-08-05 | 2014-03-13 | Sucampo Ag | Method for treating schizophrenia |
| CN103664726A (zh) * | 2012-08-31 | 2014-03-26 | 南京华狮化工有限公司 | 氘代比马前列素或其衍生物、它们的制备方法及其应用 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| EP3246046A4 (en) * | 2015-01-13 | 2018-12-05 | Kyoto University | Agent for preventing and/or treating amyotrophic lateral sclerosis |
| WO2018094116A1 (en) * | 2016-11-17 | 2018-05-24 | Retrotope, Inc. | Isotopically modified components and therapeutic uses thereof |
| US20200206309A1 (en) * | 2017-07-27 | 2020-07-02 | The Mclean Hospital Corporation | METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONS |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60146826A (ja) * | 1983-12-30 | 1985-08-02 | Hisanobu Kaitani | 向精神病薬 |
| JPH0761944B2 (ja) * | 1989-11-22 | 1995-07-05 | 株式会社アールテック・ウエノ | 脳機能改善処置剤 |
| JPH07291867A (ja) * | 1994-04-28 | 1995-11-07 | Sagami Chem Res Center | 神経成長因子産生促進剤 |
| JPH08277222A (ja) * | 1995-04-05 | 1996-10-22 | Green Cross Corp:The | 神経疾患の予防治療剤 |
| US6043224A (en) * | 1996-09-05 | 2000-03-28 | The Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| EP0947195A4 (en) * | 1997-03-14 | 1999-12-01 | Toray Industries | NERVOUS CELL PROTECTIVE AGENTS |
| JPH11228417A (ja) * | 1998-02-06 | 1999-08-24 | Teijin Ltd | 神経障害治療剤 |
| SE9803761D0 (sv) * | 1998-11-04 | 1998-11-04 | Synphora Ab | Method to avoid increased iridial pigmentation during prostaglandin treatment |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| JP2000351733A (ja) * | 1999-04-09 | 2000-12-19 | Osaka Bioscience Institute | 神経栄養因子様低分子化合物 |
| KR20020016933A (ko) * | 1999-08-05 | 2002-03-06 | 야스이 쇼사꾸 | 신경 장해 치료제 |
| JP4000505B2 (ja) * | 1999-12-01 | 2007-10-31 | 第一三共株式会社 | 緑内障を治療するための併用剤 |
| GB0014356D0 (en) * | 2000-06-12 | 2000-08-02 | Colover Jack | Treatment of multiple sclerosis |
| US20030018079A1 (en) * | 2000-11-13 | 2003-01-23 | Richardson Helene | Treatment |
| US20040122100A1 (en) * | 2001-03-16 | 2004-06-24 | Shuh Narumiya | Remedies for post-traumatic stress disorder |
| BR0209063A (pt) * | 2001-04-19 | 2004-08-10 | Teika Pharmaceutical Co Ltd | Medicamentos e kits de uso medicinal |
| JP4300347B2 (ja) * | 2002-01-29 | 2009-07-22 | 参天製薬株式会社 | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 |
| IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
| JP4482726B2 (ja) * | 2002-08-29 | 2010-06-16 | 参天製薬株式会社 | Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 |
| CN1214794C (zh) * | 2003-09-08 | 2005-08-17 | 秦正红 | 前列腺素a1在制备治疗脑缺血性中风疾病的药物中的用途 |
| WO2005116027A2 (en) * | 2004-05-26 | 2005-12-08 | Pfizer Limted | Indazole and indolone derivatives and their use as pharmaceuticals |
| WO2006052899A2 (en) | 2004-11-08 | 2006-05-18 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders |
| AU2006209072B2 (en) * | 2005-01-27 | 2011-02-24 | Sucampo Ag | Method and composition for treating central nervous system disorders |
| WO2007134136A2 (en) * | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20090062561A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched latanoprost |
| CN101176735A (zh) * | 2007-12-03 | 2008-05-14 | 苏州大学 | 一种治疗缺血性脑损伤的组合制剂 |
| JP5222608B2 (ja) * | 2008-03-31 | 2013-06-26 | カゴメ株式会社 | 抗不安作用剤 |
| CA2860453C (en) * | 2011-01-24 | 2020-04-28 | Inceptum Research & Therapeutics, Inc. | Compositions comprising a prostaglandin for treating neuropsychiatric conditions |
-
2012
- 2012-01-24 CA CA2860453A patent/CA2860453C/en not_active Expired - Fee Related
- 2012-01-24 WO PCT/CA2012/050037 patent/WO2012100347A1/en not_active Ceased
- 2012-01-24 JP JP2013549683A patent/JP6023082B2/ja not_active Expired - Fee Related
- 2012-01-24 US US13/981,360 patent/US9259409B2/en not_active Expired - Fee Related
- 2012-01-24 EP EP12739892.3A patent/EP2667875A4/en not_active Withdrawn
-
2016
- 2016-01-06 US US14/989,453 patent/US20160113942A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100260573B1 (ko) | 간담즙성 질병 치료제 | |
| JP2023030072A (ja) | 併用療法 | |
| ES2235158T3 (es) | Utilizacion de fluprostenol isopropil ester para el tratamiento del glaucoma y de la hipertension ocular. | |
| JP2024543976A5 (enExample) | ||
| JP6023082B2 (ja) | 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物 | |
| US5194429A (en) | Ocular hypotensive agents | |
| US20100331410A1 (en) | Biaryl Amides | |
| NZ501834A (en) | Prostaglandin derivatives 13,14-dihydro-17-(3-fluorophenyl)-18,19,20-trinor-PGF2 for the treatment of glaucoma without increased melanin concentration in the eyes (iris) | |
| JP2015528463A (ja) | ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下 | |
| JP2001514628A (ja) | 緑内障治療に用いるための１３−チアプロスタグランジン | |
| US20040023954A1 (en) | 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma | |
| CN1237157A (zh) | 作为眼压降低剂的前列腺素的顺式－△4类似物 | |
| CN107106573A (zh) | 用于治疗青光眼和眼压过高的前列腺素偶联物和衍生物 | |
| JP2022510587A5 (enExample) | ||
| CN101146541B (zh) | 用于治疗中枢神经系统疾病的方法和组合物 | |
| JP2014511825A (ja) | サイトカイン活性の調節方法 | |
| JP2017534658A5 (enExample) | ||
| TWI403324B (zh) | 醫藥組成物 | |
| RU2748837C2 (ru) | Новое производное простагландина | |
| JP2022509765A5 (enExample) | ||
| JP3183615B2 (ja) | 肝・胆道系疾患処置剤 | |
| CN106458859B (zh) | 作为治疗性化合物的新型ep4激动剂 | |
| AU2017203092B2 (en) | Method for treating schizophrenia | |
| JP2021529189A5 (enExample) | ||
| JP5566912B2 (ja) | プロスタグランジン活性を有する置換シクロペンタン類 |